Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 74

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 74
---
    |             | $24.70 |    |                 |   478,621 |     |    |     |    |
| Total                                                         |     |                  | 11,709,003 |     |    |     |    |             | $18.12 |    |                 | 3,660,355 |     |    |     |    |

(1) Consists of the 2018 Plan, the 2019 Plan and the 2019 Employee Stock Purchase Plan (the “ESPP” ). The shares of common stock underlying any awards that are cancelled, forfeited or repurchased under our 2018 Plan will be added back to the shares of common stock available for issuance under our 2019 Plan. We no longer make grants under our 2018 Plan. The number of shares of our common stock reserved for issuance under the 2019 Plan is subject to an automatic increase on January 1 of each calendar year through January 1, 2029, in an amount equal to 5.0% of the total number of shares of our capital stock outstanding on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Board. The number of shares of our common stock reserved for issuance under the ESPP is subject to an automatic increase on January 1 of each calendar year through January 1, 2029, by the lesser of (a) 1.0% of the total number of shares of our common stock outstanding on the last day of the calendar month before the date of the automatic increase, and (b) 1,500,000 shares; provided that before the date of any such increase, the Board may determine that such increase will be less than the amount set forth in clauses (a) and (b). On January 1, 2025, the number of shares of our common stock reserved for issuance under the 2019 Plan and the ESPP were increased by 2,416,904 and 483,380, respectively, pursuant to the automatic increase provisions of such plans.

(2) Includes the unvested portion of the 2024 Executive PSUs. The weighted-average exercise price in Column (b) does not take the unvested portion of these awards into account. For additional information, please refer to “Executive Compensation—Compensation Discussion and Analysis—2024 Executive Compensation Program—Equity-Based Incentive Awards” above.

(3) Consists